HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Carcinoma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HMBD-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HMBD-001 overview
HMBD-001 is under development for the treatment of solid tumors including esophageal squamous cell carcinoma (ESCC), squamous non-small cell lung carcinoma, metastatic castration resistant prostate cancer (mCRPC), bladder cancer, triple-negative breast cancer (TNBC), cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, esophageal cancer, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma and head and neck cancer squamous cell carcinoma and lung cancer. The therapeutic candidate is developed based on ONTarget, mAbPredict, mAbHits and mAbAdvance technologies. It acts by targeting receptor tyrosine protein kinase ERBB3 (HER3). It is administered through intravenous route. It is being developed based on Rational Antibody Discovery (RAD) platform.
Hummingbird Bioscience overview
Hummingbird Bioscience (Hummingbird) is a biotechnology company that discover and develops drugs to treat cancer, autoimmune diseases and infectious disorders. The company is investigating HMBD-001, an anti-HER3 neutralizing antibody to treat solid tumors; HMBD-002, an anti-vista neutralizing antibody for the treatment of cancer; and HMBD-004 for multiple myeloma. It is also evaluating COVID-19 mAb, a SARS-CoV-2 neutralizing antibody for the treatment of SARS-CoV-2 virus. Hummingbird employs its proprietary mAbPredict platform to provide rational antibody discovery that enables targeted identification and isolation of antibodies on a target protein and mAbHits platform that controls the immune system response to optimize the production of a higher number of antibodies against the desired epitopes. The company has operations in the US and Singapore. Hummingbird is headquartered in Singapore.
For a complete picture of HMBD-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
